Is NCT06389136 recruiting in Fayetteville, AR?

Yes, NCT06389136 is currently recruiting participants at its Fayetteville, AR location. This atopic dermatitis clinical trial is actively enrolling qualified participants.

How do I join the atopic dermatitis clinical trial in Fayetteville?

To join this clinical trial in Fayetteville, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Fayetteville clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Atopic Dermatitis Clinical Trial in Fayetteville, AR

About This Atopic Dermatitis Study in Fayetteville

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study aims to provide data on the efficacy and safety of upadacitinib at different doses in adult participants with moderate to severe AD. Upadacitinib is an approved drug for the treatment of moderate to severe atopic dermatitis (AD). This stud

Sponsor: AbbVie

Who Can Participate

Inclusion Criteria

Chronic AD with onset of symptoms at least 3 years prior to Baseline and subject meets Hanifin and Rajka criteria.

Participant meets all the following disease activity criteria at Baseline Visit:

Eczema Area and Severity Index (EASI) score \>= 12;

validated Investigator´s Global Assessment for AD (vIGA-AD) score \>= 3;

Body surface area (BSA) involvement of \>= 10% in a majority of subjects (\>= 50% of the overall study population)

Baseline weekly average of daily Worst Pruritus-Numerical Rating Scale (WP-NRS) \>= 4. Note: The Baseline weekly average of daily WP-NRS will be calculated from the 7 consecutive days immediately preceding the Baseline Visit. A minimum of 4 daily scores out of the 7 days is needed.

Inadequate response to dupilumab treatment after at least 4 months of current use.

Particpant has applied a topical emollient (an additive-free, bland emollient moisturizer) twice daily for at least 7 days before the Baseline Visit and for the duration of the study. Note: Subject may use prescription moisturizers or moisturizers containing ceramide, urea, filaggrin degradation products or hyaluronic acid if such moisturizers were initiated before the Screening visit.

Exclusion Criteria

Meeting any of the following conditions at Baseline:

Other active skin diseases or skin infections (bacterial, fungal, or viral) requiring systemic treatment within 4 weeks of the Baseline Visit or would interfere with assessment of AD lesions;

Two or more past episodes of herpes zoster, or one or more episodes of disseminated herpes zoster;

One or more past episodes of disseminated herpes simplex (including eczema herpeticum);

HIV infection defined as confirmed positive anti- HIV Ab test;

Participants with current or past history of infection including, Evidence of Hepatitis B virus (HBV) or Hepatitis C virus (HCV);

Active TB or meet TB exclusionary parameters (specific requirements for TB testing are provided in the operations manual);

For Japan: Positive result of beta-D-glucan (screening for Pneumocystis jirovecii infection) or two consecutive indeterminate results of beta-D-glucan during the Screening Period;

Active infection(s) requiring treatment with intravenous anti-infectives within 30 days, or oral/intramuscular anti-infectives within 14 days prior to the Baseline Visit;

Chronic recurring infection and/or active viral infection that, based on the investigator's clinical assessment, makes the subject an unsuitable candidate for the study;

COVID-19 infection: In subjects who tested positive for COVID-19, at least 5 days must have passed between a COVID-19 positive test result and the Baseline visit of asymptomatic subjects. Subjects with mild/moderate COVID-19 infection can be enrolled if fever is resolved without use of antipyretics for 24 hours and other symptoms improved, or if 5 days have passed since the COVID-19 positive test result (whichever comes last). Subjects may be rescreened if deemed appropriate by the investigator based upon the subject's health status.

At Baseline any of the following medical diseases or disorders:

Recent (within past 6 months) cerebrovascular accident, myocardial infarction, coronary stenting, and aorto-coronary bypass surgery or venous thromboembolism;

Any unstable clinical condition which, in the opinion of the investigator would put the subject at risk by participating in the protocol;

Diagnosed active parasitic infection, suspected or high risk of parasitic infection unless clinical (and if necessary) laboratory assessment have ruled out active infection before randomization;

History of an organ transplant which requires continued immunosuppression;

History of an allergic reaction or significant sensitivity to constituents of the study drug (and its excipients) and/or other products in the same class;

History of GI perforation (other than due to appendicitis or mechanical injury), diverticulitis, or significantly increased risk for GI perforation per investigator judgment;

Conditions that could interfere with drug absorption including but not limited to short bowel syndrome or gastric bypass surgery including sleeve gastrectomy; subjects with a history of gastric banding/segmentation are not excluded;

History of malignancy except for successfully treated NMSC or localized carcinoma in situ of the cervix.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Fayetteville?

Yes, this clinical trial (NCT06389136) has an active research site in Fayetteville, AR that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Atopic Dermatitis Treatment Options in Fayetteville, AR

If you're searching for atopic dermatitis treatment options in Fayetteville, AR, this clinical trial (NCT06389136) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Fayetteville research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced atopic dermatitis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all atopic dermatitis clinical trials near you to find additional studies recruiting in your area.

Atopic Dermatitis Clinical Trial in Fayetteville, AR

Expert Care in Fayetteville

IRB Approved

No-Cost Care

Apply for This Fayetteville Location

Why Participate?

Simple Process